North America Companion Diagnostics Market

North America Companion Diagnostics Market size was valued at USD 3.9 billion in 2025 and is forecast to grow from USD 4.3 billion in 2026 to reach USD 7.0 billion by 2031, at a CAGR of 12.5%.

Description

The North America Companion Diagnostics Market size was valued at USD 3.9 billion in 2025 and is forecast to grow from USD 4.3 billion in 2026 to reach USD 7.0 billion by 2031, at a CAGR of 12.5%. Companion diagnostics are regulatory-approved tests that identify specific biomarkers to determine patient eligibility for targeted therapies, enabling precision-medicine approaches that match treatment selection to individual genetic and molecular tumor profiles rather than one-size-fits-all prescribing. The market sits at the intersection of molecular diagnostics, precision oncology, and drug-diagnostic co-development, making it one of the most closely watched enabling technologies across the regional personalized-healthcare value chain.

Demand for companion diagnostic platforms remains anchored by the rising prevalence of cancer and expanding targeted-therapy pipelines, growing biomarker-driven drug approvals, and favorable regulatory frameworks supporting drug-diagnostic co-development across the United States, Canada, and Mexico. Beyond oncology, companion diagnostics continue to enable applications in emerging biomarker targets such as HER2-ultralow, KRAS G12C, and NTRK gene fusions that require precise, patient-specific molecular testing. Rising healthcare expenditure, expanding next-generation-sequencing adoption, and continued payer recognition of diagnostics as cost-containment tools are sustaining consumption even as the region transitions toward broader, multi-biomarker testing panels.

Table of Contents

  • Product Overview

    1. Market Definition

    2. Scope of the Market

      1. Markets Covered

      2. Years Considered for Study

      3. Key Market Segmentations

  • Research Methodology

    1. Objective of the Study

    2. Baseline Methodology

    3. Key Industry Partners

    4. Major Association and Secondary Sources

    5. Forecasting Methodology

    6. Data Triangulation & Validation

    7. Assumptions and Limitations

  • Executive Summary

    1. Overview of the Market

    2. Overview of Key Market Segmentations

    3. Overview of Key Market Players

    4. Overview of Key Regions/Countries

    5. Overview of Market Drivers, Challenges, Trends

  • Voice of Customer

  • North America Companion Diagnostics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Product (Assays, Kits & Reagents, Instruments, Software & Services)

      2. By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Others)

      3. By End User (Pharmaceutical & Biotechnology Companies, Reference Laboratories, Hospitals & Diagnostic Centers, Others)

      4. By Country

      5. By Company (2025)

    3. Product Map

  • United States Companion Diagnostics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Product

      2. By Application

      3. By End User

  • Canada Companion Diagnostics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Product

      2. By Application

      3. By End User

  • Mexico Companion Diagnostics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Product

      2. By Application

      3. By End User

  • Market Dynamics

    1. Drivers

    2. Challenges

  • Market Trends & Developments

    1. Merger & Acquisition (If Any)

    2. Product Launches (If Any)

    3. Recent Developments

  • North America Companion Diagnostics Market: SWOT Analysis

  • Porter's Five Forces Analysis

    1. Competition in the Industry

    2. Potential of New Entrants

    3. Power of Suppliers

    4. Power of Customers

    5. Threat of Substitute Products

  • Competitive Landscape

    1. F. Hoffmann-La Roche Ltd

      1. Business Overview

      2. Products & Services

      3. Recent Developments

      4. Key Personnel

      5. SWOT Analysis

    2. Agilent Technologies, Inc.

    3. QIAGEN N.V.

    4. Abbott Laboratories

    5. Thermo Fisher Scientific Inc.

    6. Illumina, Inc.

    7. Foundation Medicine, Inc.

    8. Myriad Genetics, Inc.

    9. bioMérieux SA

    10. Guardant Health, Inc.

  • Strategic Recommendations

  • About Us & Disclaimer

    • Methodology